FDA approves first treatment for Ebola, a Regeneron antibody cocktail

Enlarge / Staff from South Sudan's Health Ministry pose with protective suits during a drill for Ebola preparedness conducted by the World Health Organization (WHO). (credit: Getty | Patrick Meinhardt)

The Food and Drug Administration on Tuesday issued the first-ever approval for a therapy against Ebola virus disease.

Though the Ebola vaccine, Ervebo, earned approval late last year and proved 97.5 percent effective in preliminary trials, the newly approved therapy may be useful in addressing an ongoing outbreak in Democratic Republic of Congo, which began in June. The FDA's approval may also boost the outlook for similar therapies being developed for COVID-19, which may become available before a vaccine.

The newly approved Ebola treatment, called Inmazeb (aka REGN-EB3), is a combination of three monoclonal antibodies made by Regeneron Pharmaceuticals. The antibodies target the only protein on the outside of Ebola virus particles, the glycoprotein. Ebola uses its glycoprotein to attach to and enter human cells, sparking infection. The cocktail of antibodies glom on to the protein, keeping it from invading cells.

Read 9 remaining paragraphs | Comments